反应详情

温度

40 °C

Dissolve 3-tert-butoxycarbonyl-6-(5-carboxypyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (300 mg, 0.67 mmol) in DMF (5.0 mL). Treat successively with HATU (305 mg, 0.802 mmol), N,N-diisopropylethylamine (140 μL, 0.804 mmol) and 2-fluoro-4-(trifluoromethyl)benzylamine (260 mg, 1.34 mmol). Stir overnight at 40° C. Dilute the mixture with water, extract three times with EtOAc, dry over anhydrous Na2SO4, and concentrate in vacuo. Purify by chromatography on silica gel eluting with hexane/EtOAc (3:1) to give 3-tert-butoxycarbonyl-7-chloro-6-[5-(2-fluoro-4-trifluoromethyl-benzylcarbamoyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a foam (409 g, 98%). Use a method similar to the General Procedure 1-4 to give, after basic work-up and a method similar to the General Procedure 2-1, the title compound as an off-white solid. MS (APCI+) m/z: 524 (M+H)+.

1. extractionextract three times with EtOAc
2. dry with materialdry over anhydrous Na2SO4
3. concentrationconcentrate in vacuo
4. customPurify by chromatography on silica gel eluting with hexane/EtOAc (3:1)